TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

Transcenta, biologics, antibody

TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

contact 中文


R&D

Discovery

Employing a unique antibody generation platform based on Immune Tolerance Breaking Technology to generate therapeutic candidate leads with differentiated biological profile and enhanced druggability attributes.

Translational Research

Our translational research platform enables us to model tumor responses to our investigational agents and to better understand PK/PD profiles, which guides design and conduct of clinical study.

Process Development

We can leverage both classical fed-batch and perfusion-based continuous bioprocessing technologies to enable fast-to-IND and fast-to-market process development.

Clinical Development

Based in Beijing, Shanghai, Guangzhou and Princeton, US, our teams at global clinical development centers and regulatory teams have extensive knowledge and experience in designing and executing clinical trials at all stages.

Manufacturing

Equipped with a flexible modular manufacturing facility and advanced next-generation perfusion bioprocessing platform, we are able to significantly accelerate process development and reduce the cost of manufacturing.

Global Collaboration

Benefited from the global network and industry resources of our prominent shareholders with deep biotech expertise, we have forged multiple forms of important strategic cooperation with leading domestic and international pharmaceutical companies and equipment suppliers.